KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Acquisitions & Divestments: 2011-2023

Historic Change in Acquisitions & Divestments for Esperion Therapeutics (ESPR) over the last 11 years, with Dec 2023 value amounting to $42.5 million.

  • Esperion Therapeutics' Change in Acquisitions & Divestments rose 250.00% to $17.5 million in Q2 2023 from the same period last year, while for Jun 2023 it was $105.5 million, marking a year-over-year increase of 138.99%. This contributed to the annual value of $42.5 million for FY2023, which is 37.50% down from last year.
  • According to the latest figures from FY2023, Esperion Therapeutics' Change in Acquisitions & Divestments is $42.5 million, which was down 37.50% from $68.0 million recorded in FY2022.
  • In the past 5 years, Esperion Therapeutics' Change in Acquisitions & Divestments registered a high of $99.5 million during FY2019, and its lowest value of $39.1 million during FY2020.
  • Over the past 2 years, Esperion Therapeutics' median Change in Acquisitions & Divestments value was $55.3 million (recorded in 2022), while the average stood at $55.3 million.
  • Data for Esperion Therapeutics' Change in Acquisitions & Divestments shows a maximum YoY plummeted of 60.66% (in 2020) over the last 5 years.
  • Yearly analysis of 4 years shows Esperion Therapeutics' Change in Acquisitions & Divestments stood at $99.5 million in 2019, then plummeted by 60.66% to $39.1 million in 2020, then reached $68.0 million in 2022, then slumped by 37.50% to $42.5 million in 2023.